Shandong Xinhua Pharmaceutical Co., Ltd

Hualu Network Group 中文版

Investor Relation

Information transparency and trust in peers

Investor Relation

INTERIM REPORT

Reply Slip for the First Extraordinary General Meeting for the Year 2025

Proxy Form for the First Extraordinary General Meeting for the Year 2025

Notice of Extraordinary General Meeting

Proposed Amendments to the Articles of Association, the Rules and Procedures for General Meetings, the Rules and Procedures for Board Meetings and Notice of Extraordinary General Meeting

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2025

Overseas Regulatory Announcement-Announcement on obtaining Notice of Approval for Drug Clinical Trials

Overseas Regulatory Announcement-Announcement on Ursodeoxycholic Acid Capsules of subsidiary having obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Sildenafil Citrate Orodispersible tablets having obtained Drug Registration Certificate

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2025

Overseas Regulatory Announcement-Announcement on Clarithromycin for Suspension of the Subsidiary Having Obtained Drug Registration Certificate

总条数: 30条

＜ 1 2 3 ＞

跳转到: 页